scholarly journals Postantibiotic Effects of ABT-773 and Amoxicillin-Clavulanate against Streptococcus pneumoniae andHaemophilus influenzae

2001 ◽  
Vol 45 (12) ◽  
pp. 3613-3615 ◽  
Author(s):  
Melinda M. Neuhauser ◽  
Jennifer L. Prause ◽  
Larry H. Danziger ◽  
Susan L. Pendland
Keyword(s):  
Streptococcus Pneumoniae ◽  
Haemophilus Influenzae ◽  
Clinical Isolates ◽  
Postantibiotic Effect ◽  
Amoxicillin Clavulanate

ABSTRACT This study determined the postantibiotic effect (PAE) of ABT-773 versus that of amoxicillin-clavulanate against clinical isolates ofStreptococcus pneumoniae and Haemophilus influenzae. The PAEs of ABT-773 and amoxicillin-clavulanate ranged from 2.3 to 6.0 h and 0 to 2.2 h against S. pneumoniae and from 2.7 to 9.1 h and 0 to 0.8 h againstH. influenzae, respectively.

scholarly journals 1582. Delafloxacin Activity Against Drug-Resistant Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, and Moraxella catarrhalis from US Medical Centers (2014–2018)

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S577-S578
Author(s):  
Dee Shortridge ◽  
Jennifer M Streit ◽  
Michael D Huband ◽  
Robert K Flamm
Keyword(s):  
Streptococcus Pneumoniae ◽  
Haemophilus Influenzae ◽  
Moraxella Catarrhalis ◽  
Active Agent ◽  
The United States ◽  
Multidrug Resistant ◽  
In Vitro Susceptibility ◽  
Amoxicillin Clavulanate ◽  
Tract Infections

Abstract Background Delafloxacin (DLX) is an anionic fluoroquinolone (FQ) antimicrobial that was approved in 2017 by the United States (US) Food and Drug Administration for the treatment of acute bacterial skin and skin structure infections. DLX recently successfully completed a clinical trial for the treatment of community-acquired bacterial pneumonia (CABP). In the present study, in vitro susceptibility (S) results for DLX and comparator agents were determined for CABP pathogens including Streptococcus pneumoniae (SPN), Haemophilus influenzae (HI), H. parainfluenzae (HP) and Moraxella catarrhalis (MC) clinical isolates from US hospitals participating in the SENTRY Program during 2014–2018. Methods A total of 1,975 SPN, 1,128 HI, 684 MC, and 43 HP isolates were collected from community-acquired respiratory tract infections (CARTI) during 2014–2018 from US hospitals. Sites included only 1 isolate/patient/infection episode. Isolate identifications were confirmed at JMI Laboratories. Susceptibility testing was performed according to CLSI broth microdilution methodology, and CLSI (2019) breakpoints were applied where applicable. Other antimicrobials tested included levofloxacin (LEV) and moxifloxacin (MOX; not tested in 2015). Multidrug-resistant (MDR) SPN isolates were categorized as being nonsusceptible (NS) to amoxicillin-clavulanate, erythromycin, and tetracycline; other SPN phenotypes were LEV-NS or penicillin (PEN)-NS. β-Lactamase (BL) presence was determined for HI, HP, and MC. Results The activities of the 3 FQs are shown in the table. The most active agent against SPN was DLX, with the lowest MIC50/90 values of 0.015/0.03 mg/L. DLX activities were similar when tested against the MDR or PEN-NS for SPN phenotypes. LEV-NS isolates had DLX MIC50/90 results of 0.12/0.25 mg/L. DLX was the most active FQ against HI, HP, and MC. BL presence did not affect FQ MIC values for HI or MC; only 2 HP isolates were BL-positive. Conclusion DLX demonstrated potent in vitro antibacterial activity against SPN, HI, HP, and MC. DLX was active against MDR SPN that were NS to the agents commonly used as treatments for CABP. DLX had excellent activity against LEV-NS SPN. These data support the continued study of DLX as a potential treatment for CABP. Disclosures All authors: No reported disclosures.

scholarly journals Antimicrobial Activities and Postantibiotic Effects of Clarithromycin, 14-Hydroxy-Clarithromycin, and Azithromycin in Epithelial Cell Lining Fluid against Clinical Isolates ofHaemophilus influenzae and Streptococcus pneumoniae

1999 ◽  
Vol 43 (5) ◽  
pp. 1291-1293 ◽  
Author(s):  
Kimberly L. Bergman ◽  
Keith M. Olsen ◽  
Tom E. Peddicord ◽  
Paul D. Fey ◽  
Mark E. Rupp
Keyword(s):  
Antimicrobial Activity ◽  
Streptococcus Pneumoniae ◽  
Epithelial Cell ◽  
Haemophilus Influenzae ◽  
Antimicrobial Activities ◽  
Postantibiotic Effect ◽  
Drug Concentrations ◽  
Ofhaemophilus Influenzae ◽  
Cell Lining ◽  
Epithelial Cell Lining

ABSTRACT The antimicrobial activity of concentrations of selected macrolides found in epithelial cell lining fluid was investigated. Clarithromycin demonstrated greater potency and a significantly longer postantibiotic effect (PAE) than azithromycin againstStreptococcus pneumoniae. Azithromycin displayed greater potency, faster killing, and a longer PAE than clarithromycin againstHaemophilus influenzae. Drug concentrations in epithelial cell lining fluid similar to those found in tissue did not improve the synergistic potential of 14-hydroxy-clarithromycin and indicate that a maximal PAE may exist despite increasing concentrations of drug.

scholarly journals Determination of antimicrobial action of "Apicold oral spray"

2021 ◽  
pp. 66-70
Author(s):  
Anatoly L. Kosakovsky ◽  
Oksana M. Golovnya ◽  
Svitlana G. Gunko ◽  
Ilona A. Kosakivska
Keyword(s):  
Staphylococcus Aureus ◽  
Candida Albicans ◽  
Streptococcus Pneumoniae ◽  
Haemophilus Influenzae ◽  
Streptococcus Pyogenes ◽  
Moraxella Catarrhalis ◽  
Antimicrobial Effect ◽  
Antimicrobial Action ◽  
Clinical Isolates ◽  
Fungicidal Action

Introduction: The causative agents of acute tonsillopharyngitis are viruses and bacterial flora. Treatment of acute pharyngitis is mainly local, which includes aerosols with antiseptics. Aim: Study of antimicrobial action of "Apicold oral spray" on clinical isolates of microorganisms Streptococcus pyogenes, Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Moraxella catarrhalis and Candida albicans isolated from patients' oropharynx in patients. Material and methods: The effect of Apicold Oral Spray (manufactured by APIPHARMA doo) on clinical isolates of Streptococcus pyogenes, Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Moraxella catarrhalis, and Candida albicans in Ukrainian patients was studied. Antimicrobial activity was assessed after 5, 10 and 20 minutes of action of one dose of "Apicold oral spray" on microorganisms. Bactericidal and fungicidal action (inhibition of cell growth of microorganisms) is expressed as a percentage according to the control. Results and discussion: Apicold Oral Spray has a 100% antimicrobial effect after 5 minutes on clinical isolates of Streptococcus pyogenes, Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Moraxella catarrhalis and Candida albicans (complete growth inhibition of all 5 clinical isolates after 20 minutes). Conclusion: "Apicold oral spray" has a high antimicrobial effect on clinical isolates of Streptococcus pyogenes, Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Moraxella catarrhalis and Candida albicans, which is confirmed by 100% inhibition of the growth of all bacteria after 5 minutes

scholarly journals In vitro activity of thiamphenicol against Haemophilus influenzae, Streptococcus pneumoniae and Streptococcus pyogenes clinical isolates

2021 ◽  
Vol 23 (1) ◽  
pp. 92-99
Author(s):  
Nataly V. Ivanchik ◽  
Мarina V. Sukhorukova ◽  
Аida N. Chagaryan ◽  
Ivan V. Trushin ◽  
Andrey V. Dekhnich ◽  
...  
Keyword(s):  
Streptococcus Pneumoniae ◽  
Haemophilus Influenzae ◽  
Streptococcus Pyogenes ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity ◽  
Microdilution Method ◽  
Broth Microdilution Method ◽  
Clinical Breakpoints

Objective. To determine in vitro activity of thiamphenicol and other clinically available antimicrobials against clinical isolates of Haemophilus influenzae, Streptococcus pneumoniae and Streptococcus pyogenes. Materials and Methods. We included in the study 875 clinical isolates from 20 Russian cities during 2018–2019. Among tested strains, 126 were H. influenzae, 389 – S. pneumoniae, 360 – S. pyogenes. Antimicrobial susceptibility testing was performed using broth microdilution method according to ISO 20776-1:2006. AST results were interpreted according to EUCAST v.11.0 clinical breakpoints. Results. The minimum inhibitory concentrations (MICs) of thiamphenicol did not exceed 2 mg/L for 94.4% of H. influenzae strains (MIC50 and MIC90 were 0.5 and 1 mg/L, respectively). Thiamphenicol was active against 76.9% of ampicillin-resistant H. influenzae strains (MIC of thiamphenicol < 2 mg/L). The MIC of thiamphenicol was in the range of 0.06–2 mg/L for 96.7% of S. pneumoniae strains (MIC50 and MIC90 were 0.5 and 2 mg/L, respectively). The MIC of thiamphenicol for 90.6% of S. pneumoniae strains with reduced susceptibility to penicillin (MIC of penicillin > 0.06 mg/L) did not exceed 2 mg/L. A total of 88.1% of S. pneumoniae strains resistant to erythromycin were highly susceptible to thiamphenicol (MIC < 2 mg/L). The MIC of thiamphenicol did not exceed 8 mg/L for 96.1% of S. pyogenes strains (MIC50 and MIC90 were 2 and 4 mg/L, respectively). Conclusions. Thiamphenicol was characterized by relatively high in vitro activity, comparable to that of chloramphenicol, against tested strains of H. influenzae, S. pneumoniae and S. pyogenes, including S. pneumoniae isolates with reduced susceptibility to penicillin.

Sign in / Sign up

Export Citation Format

Share Document